Premarin approved for postmenopausal dyspareunia
The FDA has approved a low-dose regimen of Wyeth's Premarin Vaginal Cream (conjugated estrogens) to treat moderate-to-severe postmenopausal dyspareunia. In a 12-week randomized, double-blind study, patients treated with low-dose regimens of Premarin Vaginal Cream had significantly improved symptoms of painful sexual intercourse compared to placebo.
Premarin Vaginal Cream is already indicated for the treatment of vulvar or vaginal atrophy and kraurosis vulvae.
For more information call (800) 934-5556 or visit www.premarin.com.